European Huntington's Disease Network

European Huntington's Disease Network
Abbreviation Euro-HD Network, EHDN
Formation 2003
Type International Network
Legal status Constitution
Purpose "to advance knowledge of Huntington's disease"[1]
Headquarters Ulm, Germany
Region served
 Europe
Official language
 English & 13 others
President
 Prof G Bernhard Landwehrmeyer
Affiliations
Website euro-hd.net

The European Huntington's Disease Network (Euro-HD or EHDN) is a Europe-wide network of professionals and people affected by Huntington's disease, who collaborate to organise and perform research into the condition, and improve the care of HD-affected individuals.[2]

Huntington's disease (HD) is an incurable, genetically inherited degenerative brain condition that causes progressive impairment of motor function and cognitive decline and psychiatric symptoms.

EHDN was founded in 2003 and is financially supported by the CHDI Foundation.[2]

EHDN provides an infrastructure for multi-national observational studies and interventional clinical trials in HD; organises biannual plenary meetings attended by professionals and HD family members; supports a range of working groups focusing on aspects of the disease; and provides endorsement and seed funding for individual research projects.[2] At December 2011, EHDN had over 1000 regular members in 26 countries.[3] EHDN's activities are governed by an elected Scientific and Bioethics Advisory Committee and an Executive Committee.[2]

The core project of EHDN is the REGISTRY study, a multi-national observational project that aims to study the natural history of HD and expedite recruitment of suitable volunteers into clinical trials.[4] At December 2011, REGISTRY had enrolled over 7700 subjects in 145 sites,[5] and generated nine peer-reviewed publications.[6][7][8][9][10][11][12][13][14] The MermaiHD study of pridopidine and HORIZON study of latrepirdine in Huntington's disease were coordinated in Europe by EHDN.[15][16]

References

  1. ↑ "Constitution". EHDN. Retrieved 19 December 2011.
  2. 1 2 3 4 "About EHDN". EHDN. Retrieved 19 December 2011.
  3. ↑ "Membership". EHDN. Retrieved 19 December 2011.
  4. ↑ "REGISTRY study: description". EHDN. Retrieved 19 December 2011.
  5. ↑ "REGISTRY study: enrolment". EHDN. Retrieved 19 December 2011.
  6. ↑ Saft, C; Epplen, JT, Wieczorek, S, Landwehrmeyer, GB, Roos, RA, de Yebenes, JG, Dose, M, Tabrizi, SJ, Craufurd, D, REGISTRY Investigators of the European Huntington's Disease, Network, Arning, L (Oct 4, 2011). "NMDA receptor gene variations as modifiers in Huntington disease: a replication study". PLoS currents 3: RRN1247. doi:10.1371/currents.RRN1247. PMC 3186947. PMID 21989477. Cite uses deprecated parameter |coauthors= (help)
  7. ↑ Quarrell, OW; Handley, O; O'Donovan, K; Dumoulin, C; Ramos-Arroyo, M; Biunno, I; Bauer, P; Kline, M; Landwehrmeyer, GB (January 2012). "Discrepancies in reporting the CAG repeat lengths for Huntington's disease". European Journal of Human Genetics 20 (1): 20–6. doi:10.1038/ejhg.2011.136. PMC 3234505. PMID 21811303.
  8. ↑ López-Sendón, JL; Royuela, A, Trigo, P, Orth, M, Lange, H, Reilmann, R, Keylock, J, Rickards, H, Piacentini, S, Squitieri, F, Landwehrmeyer, B, Witjes-Ane, MN, Jurgens, CK, Roos, RA, Abraira, V, de Yébenes, JG, and the European HD, Network (July 2011). "What is the impact of education on Huntington's disease?". Movement disorders : official journal of the Movement Disorder Society 26 (8): 1489–95. doi:10.1002/mds.23385. PMID 21432905. Cite uses deprecated parameter |coauthors= (help)
  9. ↑ Vaccarino, AL; Anderson, K, Borowsky, B, Duff, K, Giuliano, J, Guttman, M, Ho, AK, Orth, M, Paulsen, JS, Sills, T, van Kammen, DP, Evans, KR, PREDICT-HD and REGISTRY Investigators, Coordinators (April 2011). "An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers". Movement disorders : official journal of the Movement Disorder Society 26 (5): 877–84. doi:10.1002/mds.23574. PMC 3157755. PMID 21370269. Cite uses deprecated parameter |coauthors= (help)
  10. ↑ Busse, M; Al-Madfai, DH, Kenkre, J, Landwehrmeyer, GB, Bentivoglio, A, Rosser, A, European Huntington's Disease, Network (Jan 21, 2011). "Utilisation of Healthcare and Associated Services in Huntington's disease: a data mining study". PLoS currents 3: RRN1206. doi:10.1371/currents.RRN1206. PMC 3034233. PMID 21304753. Cite uses deprecated parameter |coauthors= (help)
  11. ↑ Orth, M; European Huntington's Disease, Network, Handley, OJ, Schwenke, C, Dunnett, S, Wild, EJ, Tabrizi, SJ, Landwehrmeyer, GB (December 2011). "Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY". Journal of neurology, neurosurgery, and psychiatry 82 (12): 1409–12. doi:10.1136/jnnp.2010.209668. PMID 21097549. Cite uses deprecated parameter |coauthors= (help)
  12. ↑ Orth, M; Handley, OJ, Schwenke, C, Dunnett, SB, Craufurd, D, Ho, AK, Wild, E, Tabrizi, SJ, Landwehrmeyer, GB, Investigators of the European Huntington's Disease, Network (Sep 28, 2010). "Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY". PLoS currents 2: RRN1184. doi:10.1371/currents.RRN1184. PMC 2947793. PMID 20890398. Cite uses deprecated parameter |coauthors= (help)
  13. ↑ Boustany CW, Jr; Murphy, GW, Hicks GL, Jr (June 1991). "Mitral valve replacement in idiopathic hypereosinophilic syndrome". Annals of Thoracic Surgery 51 (6): 1007–9. doi:10.1016/0003-4975(91)91034-S. PMID 2039298. Cite uses deprecated parameter |coauthors= (help)
  14. ↑ Aziz, NA; Jurgens, CK, Landwehrmeyer, GB, EHDN Registry Study, Group, van Roon-Mom, WM, van Ommen, GJ, Stijnen, T, Roos, RA (Oct 20, 2009). "Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease". Neurology 73 (16): 1280–5. doi:10.1212/WNL.0b013e3181bd1121. PMID 19776381. Cite uses deprecated parameter |coauthors= (help)
  15. ↑ de Yebenes, JG; Landwehrmeyer, B, Squitieri, F, Reilmann, R, Rosser, A, Barker, RA, Saft, C, Magnet, MK, Sword, A, Rembratt, A, Tedroff, J, for the MermaiHD study, investigators (December 2011). "Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial". Lancet neurology 10 (12): 1049–1057. doi:10.1016/S1474-4422(11)70233-2. PMID 22071279. Cite uses deprecated parameter |coauthors= (help)
  16. ↑ "HORIZON Study". EHDN. Retrieved 19 December 2011.

External links


This article is issued from Wikipedia - version of the Friday, April 08, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.